Tesamorelin vs Ipamorelin: Research Comparison | Peptide Intel Hub

Tesamorelin is a stabilised 44-amino-acid analogue of native human GHRH with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-4 degradation while preserving the full 44-residue sequence. It acts at the GHRH receptor in the anterior pituitary to drive pulsatile growth-hormone release.

Ipamorelin is a selective pentapeptide agonist at the growth-hormone-secretagogue receptor (ghrelin receptor / GHS-R1a). It is engineered for clean GH-release pharmacology without the cortisol, prolactin or appetite-axis off-targets seen in earlier GHRPs such as GHRP-6 and GHRP-2.

Tesamorelin is selective for the GHRH receptor. The full 44-residue sequence preserves the native receptor-binding geometry and provides a clean GHRH-axis signal in research models — the IGF-1 response in published research follows the natural pulsatile GH release.

Ipamorelin is selective for the ghrelin receptor. The two compounds engage complementary arms of the growth-hormone axis, which is why matched panels of a GHRH analogue paired with a ghrelin agonist are one of the most common growth-hormone secretagogue research designs.

Tesamorelin has a short-to-medium pharmacokinetic half-life — typically reported around 30–40 minutes after subcutaneous research dosing — supporting a once-daily research cadence in published preclinical and translational protocols.

Ipamorelin also has a short pharmacokinetic half-life (roughly two hours in published research) and is typically used in once- or twice-daily research cadences. Both compounds are stable to standard lyophilisation and reconstitution, with similar storage and handling profiles.

Tesamorelin is used in research models of GHRH-axis signalling, hepatic-lipid research (where the extensive HIV-lipodystrophy translational literature is a reference base) and any protocol that needs the full 44-residue GHRH-receptor activation profile.

Ipamorelin is used in selective ghrelin-receptor research, in growth-hormone-axis research that needs a clean GHRP without GHRP-6 / GHRP-2 off-targets, and as the ghrelin-axis arm in combined-axis panels paired with a GHRH analogue.

Both Tesamorelin and Ipamorelin should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both tesamorelin and ipamorelin ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C only for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration for both compounds.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Tesamorelin and Ipamorelin benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose tesamorelin when the protocol targets the GHRH receptor specifically — typically hepatic-lipid research, GHRH-axis signalling work, or when leveraging the published clinical literature is part of the project design. Researchers choose ipamorelin when the protocol targets selective ghrelin-receptor signalling without the off-targets seen in earlier GHRPs. Matched panels of tesamorelin (or CJC-1295) paired with ipamorelin remain one of the most common growth-hormone-secretagogue research designs.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both Tesamorelin and Ipamorelin against a project timeline so the experimental panel is sourced under a single analytical specification window.

Tesamorelin, also known as Egrifta, is a synthetic analogue of human growth hormone-releasing hormone (PMID 21668043, PMID 19243281). In November 2010, tesamorelin received approval from the US Food and Drug Administration (FDA) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (PMID 21283099, PMID 22298602). This makes it the first and, as of 2011, only treatment specifically indicated for reducing excess abdominal fat in individuals with HIV-associated lipodystrophy (PMID 21668043). Its mechanism involves stimulating the synthesis and release of endogenous growth hormone (PMID 21668043).

In two well-designed, 26-week clinical trials in human patients with HIV-associated central fat accumulation, subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT) (PMID 21668043). These human trials demonstrated that tesamorelin significantly decreased waist circumference and VAT after 26 weeks of treatment (PMID 22298602). The reduction in VAT was maintained in the longer term for human patients who continued tesamorelin treatment until week 52 in the extension phases of these two trials (PMID 21668043). However, discontinuation of therapy during this period resulted in the reaccumulation of VAT in human patients (PMID 21668043).

Beyond fat quantity, tesamorelin has also shown effects on fat quality in human patients. A study involving participants from two completed, placebo-controlled, randomized trials of tesamorelin for central adiposity in people living with HIV (PWH) showed that tesamorelin increased both visceral adipose tissue (VAT) and subcutaneous fat (SAT) density (PMID 33756511). This increase in fat density was observed over 26 weeks, with mean VAT density increasing by +6.2 HU and mean SAT density by +4.0 HU in tesamorelin-treated participants, compared to minimal changes in the placebo group (PMID 33756511). These effects on VAT and SAT density persisted even after controlling for baseline fat area and quantity changes, suggesting that tesamorelin improves both VAT and SAT quality in PWH who experienced VAT quantity reductions (PMID 33756511).

Tesamorelin has demonstrated efficacy in addressing nonalcoholic fatty liver disease (NAFLD), a common comorbidity among people living with HIV (PMID 32701508). A randomized placebo-controlled human trial revealed that tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over a one-year period (PMID 32701508). This makes tesamorelin the first strategy shown to be effective against NAFLD in the HIV-positive population (PMID 32701508).

Further analysis of paired liver biopsy specimens from this human trial identified specific hepatic gene pathway modulations (PMID 32701508). Tesamorelin was found to increase the hepatic expression of hallmark gene sets involved in oxidative phosphorylation (PMID 32701508). Concurrently, it decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division (PMID 32701508). These findings provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver in human patients (PMID 32701508).

The changes in hepatic gene expression observed among tesamorelin-treated human participants correlated with an improved fibrosis-related gene score (PMID 32701508). Tesamorelin also reciprocally up- and downregulated curated gene sets associated with favorable and poor hepatocellular carcinoma prognosis, respectively (PMID 32701508). These results inform the understanding of the biology of pulsatile growth hormone action (PMID 32701508).

In human clinical trials, tesamorelin was generally well tolerated (PMID 21668043). During 26 weeks of therapy, treatment-emergent serious adverse events occurred in less than 4% of human patients (PMID 21668043). Most of these events were injection-site reactions (PMID 21668043).

Other adverse events observed in human patients were those known to be associated with growth hormone therapy (PMID 21668043). These included arthralgia, headache, and peripheral edema (PMID 21668043). Importantly, the extension phases of two Phase 3 human clinical trials confirmed maintenance of VAT improvements on tesamorelin treatment without adverse impact on blood glucose and lipid parameters (PMID 22298602).

While current evidence suggests tesamorelin may be useful for reducing visceral adiposity in human patients with HIV-associated lipodystrophy, potentially improving self-image, long-term clinical experience is needed to further assess the benefits and risks of therapy (PMID 21668043). Potential limitations for its use in human patients include high cost and a current lack of long-term safety and adherence data (PMID 22298602).

Ipamorelin is described as a new potent growth hormone (GH) secretagogue, identified as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) (PMID 9849822). It displays high GH releasing potency and efficacy in vitro and in vivo (PMID 9849822). In vitro, ipamorelin released GH from primary rat pituitary cells with potency and efficacy similar to GHRP-6 (PMID 9849822). This pharmacological profiling, using GHRP and GHRH antagonists, clearly demonstrated that ipamorelin, like GHRP-6, stimulates GH release via a GHRP-like receptor (PMID 9849822).

In animal models, specifically pentobarbital anesthetized rats, ipamorelin released GH with potency and efficacy comparable to GHRP-6 (PMID 9849822). In conscious swine, ipamorelin released GH with similar potency and efficacy to GHRP-6 (PMID 9849822). A key distinguishing feature of ipamorelin observed in swine was its specificity for GH release (PMID 9849822). While GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol, ipamorelin did not release ACTH or cortisol at levels significantly different from those observed after GHRH stimulation (PMID 9849822). This lack of effect on ACTH and cortisol plasma levels was evident even at doses more than 200-fold higher than the ED50 for GH release, making ipamorelin the first GHRP-receptor agonist with a selectivity for GH release similar to GHRH (PMID 9849822).

Further preclinical animal studies explored ipamorelin's effects on growth. In adult female rats, ipamorelin injected subcutaneously three times daily for 15 days dose-dependently increased longitudinal bone growth rate (LGR) from 42 microm/day in the vehicle group to 44, 50, and 52 microm/day in the treatment groups (P<0.0001) (PMID 10373343). There was also a pronounced and dose-dependent effect on body weight gain in these rats (PMID 10373343). The treatment did not affect total IGF-I levels, IGFBPs, or serum markers of bone formation and resorption in rats (PMID 10373343). In a cichlid fish model, Oreochromis mossambicus, administration of ipamorelin acetate (IPA) led to a significant and dose-dependent rise in food intake, concomitant with a significant increase in primary spermatocytes, secondary spermatocytes, and early spermatids (PMID 38996787).

Beyond its established role as a GH secretagogue, ipamorelin has been investigated in preclinical animal models for other therapeutic applications. In murine models with glucocorticoid-induced muscle loss, CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension (PMID 41476424). However, these findings are limited to animal studies (PMID 41476424).

Ipamorelin has also shown promise in animal models for alleviating cisplatin-induced weight loss. In ferrets, ipamorelin administered intraperitoneally (i.p.) inhibited cisplatin-induced weight loss on the last day of the delayed phase (48-72 hours) by approximately 24% (PMID 39043357). This effect was also observed when anamorelin, another ghrelin mimetic, was centrally administered, suggesting that brain penetration may be important for these effects (PMID 39043357). In vitro, ipamorelin inhibited electrical field stimulation (EFS)-induced contractions of isolated ferret ileum by 54.4% (PMID 39043357).

Further animal research in the cichlid fish Oreochromis mossambicus indicated that ipamorelin acetate (IPA), as a ghrelin agonist, influences the hypothalamic-pituitary-testicular axis (PMID 38996787). The administration of 30 µg of IPA resulted in a significant rise in the number of late spermatids, as well as the areas of the lobule and lumen, compared to a control group (PMID 38996787). Moreover, a significant elevation in the expression of androgen receptor protein was observed in fish treated with 30 µg of IPA (PMID 38996787). Serum concentrations of luteinizing hormone (LH) and 11-ketotestosterone (11-KT) were also significantly elevated in fish treated with either 5 or 30 µg of IPA compared to the control group (PMID 38996787). These findings suggest that ghrelin enhancement via IPA promotes germ cell development during the meiosis-I phase in tilapia, potentially mediated by stimulating 11-KT and testicular androgen receptors, and pituitary LH (PMID 38996787).

Tesamorelin and ipamorelin differ significantly in their regulatory status and the extent of human clinical evidence, particularly concerning orthopaedic and sports medicine applications. Tesamorelin is an FDA-approved drug for treating HIV-associated lipodystrophy (PMID 41476424). In contrast, ipamorelin is listed as an 'unapproved peptide' that has emerged in a 'gray market' operating largely outside regulatory oversight (PMID 41966639). Ipamorelin, along with CJC-1295, is also identified as an investigational peptide with uncertain safety profiles, product quality concerns, and widespread antidoping restrictions (PMID 42160466). Tesamorelin, CJC-1295, and ipamorelin are all recognized as growth hormone secretagogues (PMID 41490200).

Despite the expanding market and patient demand for peptides in sports medicine, human data for many of these compounds, including ipamorelin, are severely lacking. For ipamorelin, along with CJC-1295, promising effects in animal models, such as improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, have not been validated in human trials (PMID 41476424). Similarly, the claimed benefits of emerging peptide supplements like ipamorelin for musculoskeletal recovery and performance remain unsubstantiated by current human trials (PMID 42578445). A critical review notes that while peptides like ipamorelin are promoted for muscle growth and recovery, the clinical evidence supporting their use in sport is limited, with most studies examining therapeutic applications under controlled dosing regimens rather than the supraphysiological or combined protocols common in bodybuilding (PMID 41880199).

Conversely, tesamorelin, while approved for HIV-associated lipodystrophy, currently has no supporting orthopaedic evidence (PMID 41476424). The American Journal of Sports Medicine emphasizes that while peptide therapy may possess significant therapeutic and regenerative potential, it is critical for orthopaedic and sports medicine providers to understand the current lack of evidence to support the clinical use of many peptides, including ipamorelin and tesamorelin, for musculoskeletal conditions (PMID 41476424). Injectable peptides in sports medicine remain largely experimental, and clinical use should be confined to approved metabolic agents for indicated conditions and to rigorously designed research protocols (PMID 42160466).

The metabolism of growth hormone releasing peptides, including ipamorelin, poses challenges for doping control analysis (PMID 23101768). Ipamorelin is one of several growth hormone releasing peptides that have received considerable attention from sports drug testing authorities due to their ability to stimulate growth hormone release from the pituitary (PMID 23101768). With the exception of GHRP-2, these peptides, including ipamorelin, represent non-approved pharmaceuticals, yet they are readily available via internet providers (PMID 23101768).

Limited information exists on the metabolism of these substances, including ipamorelin (PMID 23101768). A comprehensive in vivo (oral and intravenous administration in rats) and in vitro (with human serum and recombinant amidase) study was performed to generate information on urinary metabolites potentially useful for routine doping controls (PMID 23101768). This research highlights the ongoing efforts to develop analytical strategies to detect these compounds, especially given the rapid distribution of new, potentially performance-enhancing compounds (PMID 23101768).

Regulatory bodies like the World Anti-Doping Agency (WADA) have responded to the growing use of peptides in sport by expanding detection technologies (PMID 41880199). However, analytical challenges persist due to peptides' structural similarity to endogenous hormones and their short half-lives (PMID 41880199). The critical review concludes that peptides, including ipamorelin, represent a new phase in performance enhancement but remain experimental substances with poorly defined long-term risks, advising that their use in both competitive and recreational settings should be considered high-risk and ethically problematic until longitudinal data clarify their safety and prevalence (PMID 41880199).

While both tesamorelin and ipamorelin demonstrate unique pharmacological profiles, significant gaps remain in translating preclinical promise to established human clinical applications, particularly for ipamorelin. For tesamorelin, although its efficacy and safety in HIV-associated lipodystrophy are well-documented in human trials, its potential for other indications appears less promising based on current data (PMID 19243281). For instance, it has no supporting orthopaedic evidence (PMID 41476424). Further, long-term safety and adherence data are still needed for tesamorelin's approved use (PMID 22298602).

For ipamorelin, the disparity between extensive preclinical animal findings and human clinical evidence is even more pronounced. Animal models have shown ipamorelin's potential in longitudinal bone growth (PMID 10373343), muscle repair when combined with CJC-1295 (PMID 41476424), and even effects on the reproductive axis in fish (PMID 38996787). However, these promising findings remain largely unvalidated in human trials for musculoskeletal applications (PMID 41476424). The current lack of rigorous human safety data for many unapproved peptides, including ipamorelin, raises potential for serious harm to human patients (PMID 41966639).

The landscape of therapeutic peptides in areas like orthopaedics and sports medicine is characterized by a rapid expansion of unapproved compounds, driven by patient demand, yet operating largely outside regulatory oversight (PMID 41966639). While peptides are considered a promising tool for various conditions (PMID 42123471), for most new peptides like ipamorelin, further studies are needed before they can be safely used in humans (PMID 42123471). Rigorous validation through well-designed human clinical trials is essential to establish the safety and efficacy of investigational peptides (PMID 42021992). Clinicians must understand the current lack of evidence to support the widespread clinical use of many therapeutic peptides for orthopaedic injuries and sports performance (PMID 41476424).

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.) (2026). PMID 41966639
• Tesamorelin. — Nature reviews. Drug discovery (2011). PMID 21283099
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026). PMID 41490200
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine (2026). PMID 41476424
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. — Drugs (2011). PMID 21668043
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. — The Annals of pharmacotherapy (2012). PMID 22298602
• Tesamorelin, a human growth hormone releasing factor analogue. — Expert opinion on investigational drugs (2009). PMID 19243281
• Tesamorelin improves fat quality independent of changes in fat quantity. — AIDS (London, England) (2021). PMID 33756511
• Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. — JCI insight (2020). PMID 32701508
• Ipamorelin, the first selective growth hormone secretagogue. — European journal of endocrinology (1998). PMID 9849822
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine (2026). PMID 42578445
• Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. — International journal of molecular sciences (2026). PMID 42123471
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. — Frontiers in aging (2026). PMID 42021992
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — The Journal of sports medicine and physical fitness (2026). PMID 41880199
• Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (1999). PMID 10373343
• The influence of ghrelin agonist ipamorelin acetate on the hypothalamic-pituitary-testicular axis in a cichlid fish, Oreochromis mossambicus. — Animal reproduction science (2024). PMID 38996787
• Metabolism of growth hormone releasing peptides. — Analytical chemistry (2012). PMID 23101768
• The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. — Physiology & behavior (2024). PMID 39043357
• Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications. — JBJS reviews (2026). PMID 42160466

Both Tesamorelin and Ipamorelin are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.